Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Changed, over the years?
The market size for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment has experienced a significant increase in the recent past. The market is projected to expand from $10.36 billion in 2024 to $13.32 billion in 2025 showcasing a compound annual growth rate (CAGR) of 28.5%. This increment during the past years can be credited to the growing occurrence of transthyretin amyloid cardiomyopathy, high prevalence of transthyretin amyloidosis among the aged population, heightened alertness among healthcare providers and patients, along with the growth in health consciousness and improvement in healthcare services.
How Much Will the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Be Worth in 2029?
In the ensuing years, the market size for transthyretin amyloid cardiomyopathy (ATTR-CM) therapy is projected to witness massive expansion. The market is set to hit a value of $35.93 billion in 2029, with a compound annual growth rate (CAGR) of 28.2%. This anticipated growth within the projected period can be ascribed to the escalating occurrence of transthyretin amyloidosis, an increase in the diagnosis of nerve disorders, surge in the aging populace, rise in requisite for specific medications for the mitigation of symptoms of this rare ailment, and a boosted demand for healthcare. The forecast period will see prominent trends such as the advent of new diagnostic technology, the creation of novel methods for therapy management, targeted and innovative treatments for transthyretin amyloidosis, and breakthroughs in diagnostic techniques inclusive of cardiac MRI techniques.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
Which is the Largest Company in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
What Are the Main Market Drivers in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?
The escalating occurrence of chronic conditions is anticipated to spur the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic illnesses are enduring issues that evolve over time and persist for a year or longer, often necessitating frequent medical attention. Factors contributing to the increase in chronic diseases include aging populations, inactive lifestyles, unhealthy food habits, rising obesity levels, and contact with environmental contaminants. The administration of transthyretin amyloid cardiomyopathy treatment aids in stabilizing transthyretin, alleviating amyloid deposition, enhancing cardiac performance, and relieving symptoms to more effectively control related chronic illnesses. For example, in September 2023, as per the data from the World Health Organization, a specialized agency of the United Nations based in Switzerland, there were 41 million deaths, or 74% of total deaths, caused by non-communicable diseases (NCDs) or chronic conditions annually. Worldwide, cardiovascular diseases accounted for 17.9 million deaths, cancer for 9.3 million, chronic respiratory illnesses for 4.1 million, and diabetes for 2.0 million. Hence, the escalating occurrence of chronic conditions is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
How Is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segments Structured?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
What Strategic Trends Are Transforming the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Top players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment landscape are centering their efforts on creating cutting-edge meds for ATTR-CM, such as oral drugs tailored to balance and steady transthyretin (TTR) proteins or decrease the accumulation of amyloid fibril in the heart. Oral medications generally refer to treatments orally administered, usually in the guise of tablets, capsules, or liquid concoctions, prescribed by health practitioners. To illustrate, in November 2024, BridgeBio Pharma Inc., a biotech firm based in the US, secured the green light from the U.S. Food and Drug Administration for Attruby (acoramidis), designed for adults suffering from transthyretin amyloid cardiomyopathy (ATTR-CM). This treatment stabilizes the TTR protein, and diminishes cardiac-related fatalities and hospital admissions. Results from clinical trials have indicated that it’s well received and rapidly beneficial, specifically addressing the underlying issue of the disease.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304
This Report Delivers Insight On:
1. How big is the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, and how is it changing globally?
2. Who are the major companies in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market, and how are they performing?
3. What are the key opportunities and risks in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market right now?
4. Which products or customer segments are growing the most in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
5. What factors are helping or slowing down the growth of the transthyretin amyloid cardiomyopathy (attr-cm) treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model